Genmab's Scores A 'Hat Trick' And Cruises 60% In A Month

Genmab's stock rose 60% in October, driven by positive results from its cancer treatments Epkinly and Rina-S, according to CEO Jan van de Winkel. Epkinly outperformed standard care in lymphoma patients, while Rina-S succeeded in a late-stage study.

Original reporting
Published Nov 20, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 3:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$GMAB
Bullish
high confidence
Mentioned
$GMAB
Relevance
8/10
AlphAI data visualization · based on investors.com
Decision brief

The 30-second read

$GMABBullishHigh
01

Why it matters

The dual trial successes constitute a material catalyst, explaining the 60% price jump and likely attracting further investor interest.

02

Market read

The news directly explains the sharp stock rally and may influence biotech sector sentiment.

03

What to watch

Upcoming FDA review timeline and competition from other lymphoma therapies.

Relevance 8/10Novelty 8/10Timing: today

Background

Genmab announced that its drug Epkinly outperformed standard of care in lymphoma patients and its ADC Rina‑S succeeded in a final‑phase study.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab stock surged 60% after reporting positive Phase III trial results for Epkinly and Rina‑S.

Expected impact

upward pressure as investors price in the successful trial outcomes

Evidence & confidence

Breakthrough oncology results are material news for a biotech and often trigger sustained price gains.

Market effects

May boost sentiment in the oncology biotech sector.

Positive for European biotech markets where Genmab is listed.

Limited to biotech investors; no broad market effect.

Counterpoint

Skeptics may question durability of trial data and potential regulatory hurdles.

Key entities

  • Genmab

    Biotech firm developing oncology therapies.

  • Epkinly

    Genmab's lymphoma drug showing positive trial results.

  • Rina‑S

    Genmab's antibody‑drug conjugate succeeding in final‑phase study.

Related articles

$GMABHighAI 8/10

Genmab (GMAB) Q3 2026 Earnings Call Transcript

Genmab reported positive phase III trial results for Epkinly, Rina-S, and petosemtamab, with Epkinly showing a hazard ratio of 0.49 in the EPCORE DLBCL-2 trial. Sales for Epkinly and Tivdak grew 47% and 9% year-over-year, respectively, to $491M and $131M in the first nine months of 2026. The company is preparing for potential launches in early lines of DLBCL and other indications.

$GMABMedAI 8/10

Why is Genmab stock sliding today?

Genmab (GMAB) shares fell 4.9% after Q3 revenue of $1.19B missed estimates, though EPS beat. Epkinly sales grew 47% but lagged Jyske Bank's forecast. Full-year guidance remained unchanged, disappointing some analysts. Higher costs reduced net profit. The company maintained its revenue and earnings outlook but did not raise it, despite recent clinical trial successes.